Xolair Approved to Reduce Allergic Reactions from Food Triggers
The U.S. Food and Drug Administration made a groundbreaking announcement on Friday, revealing that the asthma medication Xolair, also known as omalizumab, is now approved to aid individuals with food allergies in avoiding severe reactions. This marks the first time a medication has been sanctioned to diminish allergic responses triggered by accidental exposure to foods that cause allergies. Patients as young as one year old who suffer from allergies can receive injections of the drug every two to four weeks, tailored to their weight and their body’s reaction to allergens.
Improved Quality of Life for Millions
An estimated 17 million Americans are afflicted with food allergies that can lead to rapid and severe symptoms, including potentially life-threatening whole-body reactions. Those using Xolair must still steer clear of the foods that induce these reactions, like peanuts, cashews, hazelnuts, walnuts, milk products, and eggs. However, the medication enables them to tolerate higher quantities of these foods without triggering major reactions, offering a newfound sense of freedom and security.
Promising Study Results
The FDA’s decision is supported by a study spearheaded by Dr. Robert Wood from Johns Hopkins Children’s Center, funded by the National Institutes of Health. The study demonstrated that Xolair allowed approximately 68% of participants with peanut allergies to tolerate around 600 milligrams of peanut protein, a significant improvement compared to those who received placebo injections. This promising trend extended to other allergens such as tree nuts, milk, egg, and wheat.
Accessibility and Potential Risks
While Xolair has previously been used “off-label” to address food allergies, its full approval is a welcome development according to Dr. Ruchi Gupta of Northwestern University. The drug, classified as a monoclonal antibody, hinders the body’s natural response to allergens. Notably, Xolair’s list price varies from $2,900 to $5,000 per month, depending on the age of the patient. Side effects may include injection site reactions and fever, with rare occurrences of joint pain, rash, and parasitic infections.
Financial Considerations and Future Prospects
Despite the potential risks, many individuals with food allergies, particularly children and young adults, are expected to opt for Xolair. Most insured patients are likely to have lower out-of-pocket expenses. The FDA emphasizes that Xolair is not for emergency treatment of allergic reactions and should be initiated in a healthcare setting prepared to manage anaphylaxis. This groundbreaking approval of Xolair opens up new possibilities for individuals living with food allergies, promising a brighter and more secure future.